Ruiz-Roso Guerra, María BelénEcheverry Alzate, VíctorRuiz-Roso Calvo de la Mora, BaltasarQuintela, JoséBallesteros Rodrigálvarez, SandraLahera Julia, VicenteHeras Jiménez, Natalia de lasLópez Moreno, José AntonioMartín Fernández, Beatriz2023-06-172023-06-1720182072-664310.3390/nu11010011https://hdl.handle.net/20.500.14352/19079Alzheimer’s disease (AD) is the main cause of dementia and cognitive impairment. It has been associated with a significant diminution of omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) levels in the brain. Clinical trials with DHA as a treatment in neurological diseases have shown inconsistent results. Previously, we reported that the presence of phytanic acid (PhA) in standard DHA compositions could be blunting DHA’s beneficial effects. Therefore, we aimed to analyze the effects of a low PhA-concentrated DHA and a standard PhA-concentrated DHA in Apolipoprotein E knockout (ApoEengAtribución 3.0 Españajournal articlehttps://doi.org/10.3390/nu11010011https://www.mdpi.com/2072-6643/11/1/11open accessAlzheimer’sDHAApoE -/-phytanic acidinflammationneuroprotectionoxidationNeurociencias (Medicina)2490 Neurociencias